General American Investors CO Inc Vbi Vaccines Inc Transaction History

General American Investors CO Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	BUY	$2.61 - $4.17 $130,500 - $208,500	50,000 Added 2.74%	1,877,497 $6.29 Million
Q1 2021 May 03, 2021	BUY	$2.91 - $4.32 $557,881 - $828,195	191,712 Added 11.72%	1,827,497 $5.68 Million
Q4 2020 Feb 12, 2021	BUY	$2.15 - $3.5 $1.37 Million - $2.22 Million	635,185 Added 63.48%	1,635,785 $4.5 Million
Q3 2020 Oct 30, 2020	SELL	$2.77 - $6.17 $432,319 - $962,964	-156,072 Reduced 13.49%	1,000,600 $2.86 Million
Q2 2020 Aug 03, 2020	SELL	$0.87 - $3.13 $130,500 - $469,500	-150,000 Reduced 11.48%	1,156,672 $3.59 Million
Q4 2019 Feb 20, 2020	SELL	$0.48 - $1.38 $416,444 - $1.2 Million	-867,592 Reduced 39.9%	1,306,672 $1.8 Million
Q2 2019 Aug 02, 2019	BUY	$0.65 - $2.12 $266,370 - $868,776	409,800 Added 23.23%	2,174,264 $2.54 Million
Q4 2018 Feb 15, 2019	BUY	$1.22 - $2.41 $1.1 Million - $2.17 Million	900,000 Added 104.11%	1,764,464 $2.82 Million
Q2 2018 Aug 03, 2018	BUY	$2.75 - $3.85 $727,276 - $1.02 Million	264,464 Added 44.08%	864,464 $2.38 Million
Q4 2017 Feb 13, 2018	BUY	$3.29 - $5.03 $1.97 Million - $3.02 Million	600,000	600,000 $2.56 Million

688K

Ticker VBIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 258,256,992
Market Cap $5.17M
Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...

Get notified when there are updates to the investment portfolio of General American Investors CO Inc, based on Form 13F filings with the SEC.

Stay updated on General American Investors CO Inc with notifications on news.